AMRN Amarin Corp

Amarin Corporation plc (Nasdaq:AMRN) announces the following Webcast:

What: Lippert/Heilshorn Life Sciences Conference Presentation

When: March 26, 2009 @ 11:00 AM Eastern

Where: http://www.investorcalendar.com/ClientPage.asp?ID=142694

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Cheryl Lapazzo, 212-838-3777, clapazzo@lhai.com

If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=142694 or http://www.investorcalendar.com/

Amarin Corporation (Nasdaq: AMRN) is a clinical-stage biopharmaceutical company with a lead program planned to enter Phase 3 for hypertriglyceridemia. Amarin�s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin�s pipeline also includes programs in myasthenia gravis, Huntington�s disease, Parkinson�s disease and epilepsy, all of which are available for partnering. Amarin is listed in the U.S. on the NASDAQ Capital Market (�AMRN�). For more information please visit www.amarincorp.com.

Amarin (LSE:AMRN)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025

Amarin (LSE:AMRN)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025